Intestinal ferroportin expression in pediatric Crohn's disease

Inflammatory Bowel Diseases

Volumn 17, Issue 2, 2011, Pages 524-531

  Burpee, Tyler ^a,e   Mitchell, Paul ^a   Fishman, Douglas ^a,f   Islam, Shabana ^a   Nemeth, Elizabeta ^b   Westerman, Mark ^c   Wessling Resnick, Marianne ^d   Grand, Richard J ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Intrinsic LifeSciences LLC   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

anemia; Crohn's disease; ferroportin; iron

Indexed keywords

C REACTIVE PROTEIN; FERROPORTIN; HEPCIDIN; INTERLEUKIN 6; MESSENGER RNA;

ADOLESCENT; ANEMIA; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROHN DISEASE; DOWN REGULATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; IRON BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADOLESCENT; ADULT; ANEMIA, IRON-DEFICIENCY; BLOTTING, WESTERN; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CATION TRANSPORT PROTEINS; CHILD; CROHN DISEASE; DUODENUM; FEMALE; HUMANS; INTESTINAL MUCOSA; MALE; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; YOUNG ADULT;

EID: 78651296362     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21367     Document Type: Article

References (49)

1. Loftus EV Jr, Sandborn WJ,. Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am. 2002; 31: 1-20.
2. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007; 5: 1424-1429.
3. Baldassano RN, Piccoli DA,. Inflammatory bowel disease in pediatric and adolescent patients. Gastroenterol Clin North Am. 1999; 28: 445-458.
4. Mendeloff AI, Calkins BM,. The epidemiology of idiopathic inflammatory bowel disease. In:, Kirsner JB, Shorter RG, editors. Inflammatory bowel disease. Philadelphia: Lea & Febiger; 1988: 3-34.
5. Bernstein CN, Blanchard JF,. The epidemiology of Crohn's disease. Gastroenterology. 1999; 116: 1503-1504.
6. Farrokhyar F, Swarbrick ET, Irvine EJ,. A critical review of epidemiological studies in inflammatory bowel disease. Scand J Gastroenterol. 2001; 36: 2-15.
7. Kugathasan S, Judd RH, Hoffmann RG, et al. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. J Pediatr. 2003; 143: 525-531.
8. Burbige EJ, Huang SH, Bayless TM,. Clinical manifestations of Crohn's disease in children and adolescents. Pediatrics. 1975; 55: 866-871.
9. Beeken WL,. Remediable defects in Crohn disease: a prospective study of 63 patients. Arch Intern Med. 1975; 135: 686-690.
10. Thayu M, Leonard MB, Baldassano RN, et al. Prevalence of anemia in incident pediatric Crohn disease: 177. J Pediatr Gastroenterol Nutr. 2005; 41: 547-548.
11. Gasche C, Dejaco C, Waldhoer T, et al. Intravenous iron and erythropoietin for anemia associated with Crohn disease. A randomized, controlled trial. Ann Intern Med. 1997; 126: 782-787.
12. Wells CW, Lewis S, Barton JR, et al. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis. 2006; 12: 123-130.
13. Lozoff B, Brittenham GM, Wolf AW, et al. Iron deficiency anemia and iron therapy effects on infant developmental test performance. Pediatrics. 1987; 79: 981-995.
14. Oski FA, Honig AS, Helu B, et al. Effect of iron therapy on behavior performance in nonanemic, iron-deficient infants. Pediatrics. 1983; 71: 877-880.
15. Walter T, Kovalskys J, Stekel A,. Effect of mild iron deficiency on infant mental development scores. J Pediatr. 1983; 102: 519-522.
16. Grindulis H, Scott PH, Belton NR, et al. Combined deficiency of iron and vitamin D in Asian toddlers. Arch Dis Child. 1986; 61: 843-848.
17. Lozoff B, Klein NK, Nelson EC, et al. Behavior of infants with iron-deficiency anemia. Child Dev. 1998; 69: 24-36.
18. Aukett MA, Parks YA, Scott PH, et al. Treatment with iron increases weight gain and psychomotor development. Arch Dis Child. 1986; 61: 849-857.
19. Verhave M, Baldassano RN, Bousvaros A, et al. Research agenda for pediatric gastroenterology, hepatology and nutrition: chronic inflammatory bowel disease. Report of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition for the Children's Digestive Health and Nutrition Foundation. J Pediatr Gastroenterol Nutr. 2002; 35: S286-290.
20. Kulnigg S, Gasche C,. Systematic review: managing anaemia in Crohn's disease. Aliment Pharmacol Ther. 2006; 24: 1507-1523.
21. McKie AT, Marciani P, Rolfs A, et al. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol Cell. 2000; 5: 299-309.
22. Abboud S, Haile DJ,. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem. 2000; 275: 19906-19912.
23. Dupic F, Fruchon S, Bensaid M, et al. Duodenal mRNA expression of iron related genes in response to iron loading and iron deficiency in four strains of mice. Gut. 2002; 51: 648-653.
24. Zoller H, Theurl I, Koch R, et al. Mechanisms of iron mediated regulation of the duodenal iron transporters divalent metal transporter 1 and ferroportin 1. Blood Cells Mol Dis. 2002; 29: 488-497.
25. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004; 306: 2090-2093.
26. Yang F, Liu XB, Quinones M, et al. Regulation of reticuloendothelial iron transporter MTP1 (Slc11a3) by inflammation. J Biol Chem. 2002; 277: 39786-39791.
27. Yeh KY, Yeh M, Glass J,. Hepcidin regulation of ferroportin 1 expression in the liver and intestine of the rat. Am J Physiol Gastrointest Liver Physiol. 2004; 286: G385-394.
28. Ganz T, Nemeth E,. Iron imports. IV. Hepcidin and regulation of body iron metabolism. Am J Physiol Gastrointest Liver Physiol. 2006; 290: G199-203.
29. Mudter J, Neurath MF,. Il-6 signaling in inflammatory bowel disease: Pathophysiological role and clinical relevance. Inflamm Bowel Dis. 2007; 13: 1016-1023.
30. Semrin G, Fishman DS, Bousvaros A, et al. Impaired intestinal iron absorption in Crohn's disease correlates with disease activity and markers of inflammation. Inflamm Bowel Dis. 2006; 12: 1101-1106.
31. Erichsen K, Milde AM, Arslan G, et al. Low-dose oral ferrous fumarate aggravated intestinal inflammation in rats with DSS-induced colitis. Inflamm Bowel Dis. 2005; 11: 744-748.
32. Erichsen K, Ulvik RJ, Nysaeter G, et al. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. Scand J Gastroenterol. 2005; 40: 1058-1065.
33. Bodemar G, Kechagias S, Almer S, et al. Treatment of anaemia in inflammatory bowel disease with iron sucrose. Scand J Gastroenterol. 2004; 39: 454-458.
34. Gasche C, Waldhoer T, Feichtenschlager T, et al. Prediction of response to iron sucrose in inflammatory bowel disease-associated anemia. Am J Gastroenterol. 2001; 96: 2382-2387.
35. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr. 1991; 12: 439-447.
36. Ganz T, Olbina G, Girelli D, et al. Immunoassay for human serum hepcidin. Blood. 2008; 112: 4292-4297.
37. IBD Working Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. Inflammatory bowel disease in children and adolescents: recommendations for diagnosis-the Porto criteria. J Pediatr Gastroenterol Nutr. 2005; 41: 1-7.
38. Hollowell JG, van Assendelft OW, Gunter EW, et al. Centers for Disease Control and Prevention, National Center for Health Statistics. Hematological and iron-related analytes-reference data for persons aged 1 year and over: United States, 1988-94. Vital Health Stat [11]. 2005; 1-156.
39. Knutson MD, Vafa MR, Haile DJ, et al. Iron loading and erythrophagocytosis increase ferroportin 1 (FPN1) expression in J774 macrophages. Blood. 2003; 102: 4191-4197.
40. Davies PS, Enns CA,. Expression of the hereditary hemochromatosis protein HFE increases ferritin levels by inhibiting iron export in HT29 cells. J Biol Chem. 2004; 279: 25085-25092.
41. Barisani D, Parafioriti A, Bardella MT, et al. Adaptive changes of duodenal iron transport proteins in celiac disease. Physiol Genomics. 2004; 17: 316-325.
42. Zaritsky J, Young B, Wang HJ, et al. Hepcidin-a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol. 2009; 4: 1051-1056.
43. Chaston T, Chung B, Mascarenhas M, et al. Evidence for differential effects of hepcidin in macrophages and intestinal epithelial cells. Gut. 2008; 57: 374-382.
44. Mena NP, Esparza A, Tapia V, et al. Hepcidin inhibits apical iron uptake in intestinal cells. Am J Physiol Gastrointest Liver Physiol. 2008; 294: G192-198.
45. Chung B, Chaston T, Marks J, et al. Hepcidin decreases iron transporter expression in vivo in mouse duodenum and spleen and in vitro in THP-1 macrophages and intestinal Caco-2 cells. J Nutr. 2009; 139: 1457-1462.
46. Bergamaschi G, Di Sabatino A, Albertini R, et al. Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-α treatment. Haematologica. 2010; 95: 199-205.
47. Johnson D, Bayele H, Johnston K, et al. Tumour necrosis factor alpha regulates iron transport and transporter expression in human intestinal epithelial cells. FEBS Lett. 2004; 573: 195-201.
48. Laftah AH, Sharma N, Brookes MJ, et al. Tumour necrosis factor α causes hypoferraemia and reduced intestinal iron absorption in mice. Biochem J. 2006; 397: 61-67.
49. Sharma N, Laftah AH, Brookes MJ, et al. A role for tumour necrosis factor alpha in human small bowel iron transport. Biochem J. 2005; 390 (Pt 2): 437-446.